PMID- 20062995
OWN - NLM
STAT- MEDLINE
DCOM- 20100615
LR  - 20220321
IS  - 1437-160X (Electronic)
IS  - 0172-8172 (Linking)
VI  - 30
IP  - 6
DP  - 2010 Apr
TI  - Etanercept treatment reduces the serum levels of interleukin-15 and 
      interferon-gamma inducible protein-10 in patients with rheumatoid arthritis.
PG  - 725-30
LID - 10.1007/s00296-009-1356-y [doi]
AB  - Tumor necrosis factor-alpha (TNF-alpha) has an essential role in the pathogenesis 
      of rheumatoid arthritis (RA) and has been known to induce the production of 
      several inflammatory molecules in vivo. To analyze in vivo the active mechanism 
      of the TNF-alpha blocking agent, etanercept, the serum levels of the cytokine 
      interleukin-15 (IL-15) and the chemokines growth-regulated protein-alpha 
      (Gro-alpha), and interferon-gamma inducible protein-10 (IP-10) in RA patients 
      were measured. Twenty-two patients with RA were administered etanercept once or 
      twice a week for more than 6 months. The clinical and laboratory parameters were 
      measured and serum levels of IL-15, Gro-alpha, and IP-10 were determined using 
      enzyme-linked immunosorbent assay (ELISA) kits at the baseline and at 3 and 6 
      months after the initial treatment. Additionally, the production of IL-15 and 
      IP-10 by cultured synovial cells stimulated with TNF-alpha from RA patients was 
      determined by ELISA. A significant decrease in serum levels of IL-15 and IP-10 
      was observed at 3 and 6 months after initial treatment with etanercept, but not 
      in those of Gro-alpha. TNF-alpha induced production of IP-10, but not IL-15 in 
      cultured synovial cells from RA patients. This study demonstrated for the first 
      time the reduction of IP-10 and IL-15 production in RA patients as active 
      mechanisms of etanercept.
FAU - Ichikawa, Tetsuya
AU  - Ichikawa T
AD  - Department of Orthopaedic Surgery, Narita Memorial Hospital, 78 Shirakawa-cho, 
      Toyohashi, 441-8021, Japan.
FAU - Kageyama, Yasunori
AU  - Kageyama Y
FAU - Kobayashi, Hayato
AU  - Kobayashi H
FAU - Kato, Norihiko
AU  - Kato N
FAU - Tsujimura, Kunio
AU  - Tsujimura K
FAU - Koide, Yukio
AU  - Koide Y
LA  - eng
PT  - Journal Article
DEP - 20100110
PL  - Germany
TA  - Rheumatol Int
JT  - Rheumatology international
JID - 8206885
RN  - 0 (CXCL1 protein, human)
RN  - 0 (CXCL10 protein, human)
RN  - 0 (Chemokine CXCL1)
RN  - 0 (Chemokine CXCL10)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Interleukin-15)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Aged
MH  - Arthritis, Rheumatoid/*blood/*drug therapy/immunology
MH  - Cells, Cultured
MH  - Chemokine CXCL1/antagonists & inhibitors/blood
MH  - Chemokine CXCL10/*blood
MH  - Down-Regulation/drug effects/immunology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Etanercept
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/*pharmacology
MH  - Immunosuppressive Agents/*pharmacology
MH  - Interleukin-15/*blood
MH  - Male
MH  - Middle Aged
MH  - Receptors, Tumor Necrosis Factor
MH  - Synovial Membrane/drug effects/metabolism
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors/blood
EDAT- 2010/01/12 06:00
MHDA- 2010/06/16 06:00
CRDT- 2010/01/12 06:00
PHST- 2009/11/11 00:00 [received]
PHST- 2009/12/29 00:00 [accepted]
PHST- 2010/01/12 06:00 [entrez]
PHST- 2010/01/12 06:00 [pubmed]
PHST- 2010/06/16 06:00 [medline]
AID - 10.1007/s00296-009-1356-y [doi]
PST - ppublish
SO  - Rheumatol Int. 2010 Apr;30(6):725-30. doi: 10.1007/s00296-009-1356-y. Epub 2010 
      Jan 10.